CTLA4 and melanoma: also indicated that a TLR1/2 agonist enhanced the efficacy of an anti-CTLA-4 antibody by depleting regulatory T cells and increasing IFN-γ secretion from T cells to reshape the TME in a syngeneic melanoma model12.